Respiratory drug delivery offers treatment for diseases of the respiratory tract through noninvasive means to deliver either topically active medications or systemic drugs to target organs. The nose and lung are the target organs for the deposition of the aerosol drug. In asthma, drug delivery to the upper airways is needed while for alveolar lung diseases, such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis, it is important to have drug deposition deep within the lungs rather than just the upper airways.
Major Key Players of the Respiratory Drug Delivery Market are:
3M, GlaxoSmithKline plc., AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH., Philips Respironics, Merck & Co., Inc., OMRON Healthcare, Cipla Inc., and others.
The market growth of respiratory drug delivery can be attributed to factors such as the growing geriatric population globally and the rising number of patients suffering from respiratory diseases. According to the Office of Disease Prevention and Health Promotion, more than 25 million in the U.S. are suffering from asthma and 14.8 million adults have been diagnosed with COPD. Also, according to the WHO, smoking is considered to be a primary cause for COPD and more than 1 billion people inhale outdoor polluted air exposed to tobacco. These factors are leading to an upsurge in market growth.
The Respiratory Drug Delivery Market is segmented on the basis of product Formulation, Applications, Device Type, and region.
Major Formulation of Respiratory Drug Delivery Market covered are:
- Suspension Aerosols
- Solution Aerosols
- Dry Powder Formulations
Major Device Types of Respiratory Drug Delivery Market covered are:
- Metered Dose Inhalers (MDIs)
- Dry Powder Inhalers (DPIs)
- Nebulizers
Major Applications ofRespiratory Drug Delivery Market covered are:
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Cystic Fibrosis
No comments:
Post a Comment